That apart, national laboratories have also been allowed to carry out clinical testing of Covid-19, as the number of cases went past 400 in India.
The company's normalized Ebitda grew 19 per cent year on year (YoY) at Rs 42.5 crore, while margins improved to 40 per cent compared with 37 per cent clocked in the previous year quarter
Thus far in the calendar year 2018, Thyrocare had underperformed the market by falling 14% as compared to 8.6% rise in the S&P BSE Sensex till Friday.
Stock one of the top picks among analysts in health care space
Firm will expand lab centres to 25, from seven currently, and increase franchisees from 1,200 to 5,000
Health care firm's listing outshines that of Alkem and Narayana Hrudayalaya
The stock listed at Rs 665, a 49% premium compared with its issue price of Rs 446 per equity share, on the NSE.
Thyrocare has allocated 32,23,411 shares to 15 anchor investors at Rs 446 per share
Here's a quick compilation of what country's top research and brokerage houses suggest
The company's initial public offering is scheduled to close on April 29